# US 2014/0275132 A1 · Pyridinyl and pyrimidinyl sulfonamide derivatives as chemokine receptor modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0275132 A1
- Document ID: US20140275132A1
- Status: Published application
- Kind: A1
- Application number: 14/206,491
- Filed: 2014-03-12
- Published: 2014-09-18
- Earliest claimed: 2013-03-12
- Assignees: Allergan, Inc.
- Applicants: Allergan, Inc.
- Inventors: Richard L. Beard; John E. Donello; Veena Viswanath; Michael E. Garst; Haiqing Yuan; Xiaoxia Liu
- Web page: https://patentgrep.com/patent/US20140275132A1

## CPC

- C07D 409/12: linked by a chain containing hetero atoms as chain links
- A61P 3/04: Anorexiants; Antiobesity agents
- C07D 213/75: Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- C07D 213/76: to which a second hetero atom is attached (nitro radicals C07D213/61)
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 413/10: linked by a carbon chain containing aromatic rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to novel pyridine or pyrimidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with chemokine receptor modulation.

## Claims

### Claim 1

A compound represented by Formula I, an enantiomer, a diastereoisomer, a tautomer or a pharmaceutically acceptable salt thereof:
wherein:
R1 is substituted or unsubstituted heterocycle, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl or is substituted or unsubstituted C6-10 aryl;
R2 is —S—, —S(O)—, or —S(O)2—;
R3 is CR7, N or N-oxide;
R4 is CR7, N or N-oxide;
R5 is CR7, N or N-oxide;
R6 is substituted or unsubstituted heterocycle, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl or is substituted or unsubstituted C6-10 aryl;
R7 is H, substituted or unsubstituted C1-6 alkyl, halogen, substituted or unsubstituted —OR8, C2-6 alkenyl, C2-6 alkynyl, CN, C(O)R9, NR19R11, amide, urea, sulfonamide, sulfone, sulfoxide, sulfide, sulfonic acid, nitro, phosphate or phosphonic acid;
R8 is H, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted heterocycle, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl or is substituted or unsubstituted C6-10 aryl;
R9 is H, hydroxyl, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted heterocycle, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl or is substituted or unsubstituted C6-10 aryl;
R10 is H, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted heterocycle, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl, is substituted or unsubstituted C6-10 aryl or together with R11 can form a 3-10 membered ring;
R11 is H, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted heterocycle, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl, is substituted or unsubstituted C6-10 aryl or together with R10 can form a 3-10 membered ring;
R12 is H, substituted or unsubstituted C1-6 alkyl, halogen, substituted or unsubstituted —OR8, C2-6 alkenyl, C2-6 alkynyl, CN, C(O)R9, NR10R11, amide, urea, sulfonamide, sulfone, sulfoxide, sulfide, sulfonic acid, nitro, phosphate or phosphonic acid;
with the provisios
at least one of R3, R4 or R5 is N or N-oxide; and,
R1 is not benzofuran-2-yl, when R3 is CR7 and R4 is CR7 and R5 is N.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein:
R3 is N;
R4 is CR7; and
R5 is N.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein:
R1 is substituted or unsubstituted heterocycle or substituted or unsubstituted C6-10 aryl;
R3 is N;
R4 is CR7;
R5 is N;
R6 is substituted or unsubstituted C6-10 aryl;
R7 is H; and
R12 is H.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein:
R3 is CR7;
R4 is N or N-oxide;
R5 is CR7;
R6 is substituted or unsubstituted C6-10 aryl;
R7 is H; and
R12 is H.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein:
R3 is CR7;
R4 is N-oxide;
R5 is CR7;
R6 is substituted or unsubstituted C6-10 aryl;
R7 is H; and
R12 is H.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein:
R3 is CR7;
R4 is N;
R5 is CR7;
R6 is substituted or unsubstituted C6-10 aryl;
R7 is H; and
R12 is H.

### Claim 7 (depends on 1)

The compound according to claim 1, wherein:
R1 is substituted or unsubstituted heterocycle, or is substituted or unsubstituted C6-10 aryl;
R3 is CR7;
R4 is CR7;
R5 is, N;
R6 is substituted or unsubstituted C6-10 aryl;
R7 is H or halogen;
R12 is H; and
with the proviso
R1 is not benzofuran-2-yl, when R3 is CR7 and R4 is CR7 and R5 is N.

### Claim 8 (depends on 1)

The compound according to claim 1, wherein:
R1 is substituted or unsubstituted heterocycle;
R3 is CR7;
R4 is CR7;
R5 is N;
R6 is unsubstituted C6-10 aryl;
R7 is H or halogen;
R12 is H; and
with the proviso
R1 is not benzofuran-2-yl, when R3 is CR7 and R4 is CR7 and R5 is N.

### Claim 9 (depends on 1)

The compound according to claim 1, wherein:
R1 is substituted or unsubstituted C6-10 aryl;
R3 is CR7;
R4 is CR7;
R5 is N;
R6 is unsubstituted C6-10 aryl;
R7 is H or halogen; and
R12 is H.

### Claim 10 (depends on 1)

The compound according to claim 1, selected from:
N-[4-(benzylsulfanyl)pyrimidin-5-yl]-1-benzofuran-2-sulfonamide;
N-[4-(benzylsulfonyl)pyrimidin-5-yl]-1-benzofuran-2-sulfonamide;
N-[4-(benzylsulfinyl)pyrimidin-5-yl]-1-benzofuran-2-sulfonamide;
N-[3-(benzylsulfanyl)pyridin-4-yl]-1-benzofuran-2-sulfonamide;
N-[3-(benzylsulfonyl)pyridin-4-yl]-1-benzofuran-2-sulfonamide;
N-[3-(benzylsulfanyl)-1-oxidopyridin-4-yl]-1-benzofuran-2-sulfonamide;
N-[2-(benzylsulfanyl)-5-chloropyridin-3-yl]-3,4-dichlorobenzenesulfonamide;
N-[2-(benzylsulfanyl)-5-chloropyridin-3-yl]-5-chlorothiophene-2-sulfonamide;
N-[2-(benzylsulfonyl)-5-chloropyridin-3-yl]-3,4-dichlorobenzenesulfonamide;
N-[2-(benzylsulfinyl)-5-chloropyridin-3-yl]-3,4-dichlorobenzenesulfonamide;
N-[2-(benzylsulfonyl)-5-chloropyridin-3-yl]-5-chlorothiophene-2-sulfonamide;
N-[2-(benzylsulfinyl)-5-chloropyridin-3-yl]-5-chlorothiophene-2-sulfonamide;
N-[2-(benzylthio)pyridin-3-yl]-1-benzothiophene-2-sulfonamide;
N-[2-(benzylsulfonyl)pyridin-3-yl]-1-benzothiophene-2-sulfonamide;
N-[2-(benzylsulfinyl)pyridin-3-yl]-1-benzothiophene-2-sulfonamide.

### Claim 11

A method of treating a disorder associated with chemokine receptor modulation, which comprises administering to a mammal in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula I
wherein:
R1 is substituted or unsubstituted heterocycle, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl or is substituted or unsubstituted C6-10 aryl;
R2 is —S—, —S(O)—, or —S(O)2—;
R3 is CR7, N or N-oxide;
R4 is CR7, N or N-oxide;
R5 is CR7, N or N-oxide;
R6 is substituted or unsubstituted heterocycle, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl or is substituted or unsubstituted C6-10 aryl;
R7 is H, substituted or unsubstituted C1-6 alkyl, halogen, substituted or unsubstituted —OR8, C2-6 alkenyl, C2-6 alkynyl, CN, C(O)R9, NR10R11, amide, urea, sulfonamide, sulfone, sulfoxide, sulfide, sulfonic acid, nitro, phosphate or phosphonic acid;
R8 is H, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted heterocycle, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl or is substituted or unsubstituted C6-10 aryl;
R9 is H, hydroxyl, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted heterocycle, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl or is substituted or unsubstituted C6-10 aryl;
R10 is H, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted heterocycle, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl, is substituted or unsubstituted C6-10 aryl or together with R11 can form a 3-10 membered ring;
R11 is H, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted heterocycle, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl, is substituted or unsubstituted C6-10 aryl or together with R19 can form a 3-10 membered ring;
R12 is H, substituted or unsubstituted C1-6 alkyl, halogen, substituted or unsubstituted —OR8, C2-6 alkenyl, C2-6 alkynyl, CN, C(O)R9, NR10R11, amide, urea, sulfonamide, sulfone, sulfoxide, sulfide, sulfonic acid, nitro, phosphate or phosphonic acid;
with the provisios
at least one of R3, R4 or R5 is N or N-oxide; and,
R1 is not benzofuran-2-yl, when R3 is CR7 and R4 is CR7 and R5 is N.

### Claim 12 (depends on 11)

The method of claim 11, wherein the pharmaceutical composition is administered to the mammal to treat ocular inflammatory diseases or skin inflammatory diseases.

### Claim 13 (depends on 11)

The method of claim 11 wherein the mammal is a human.
